NCT03826472 is a Phase 2 clinical trial of Almond Butter in Type2 Diabetes, sponsored by Penn State University.

Who is sponsoring NCT03826472?

NCT03826472 is sponsored by Penn State University.

What drugs are being tested in NCT03826472?

Interventions in NCT03826472: Almond Butter.

What condition does NCT03826472 study?

NCT03826472 studies Type2 Diabetes.

Is NCT03826472 still recruiting?

NCT03826472 is currently completed. Last updated 9 April 2024.

Are results published for NCT03826472?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-04-09 · How we verify

NCT03826472

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Almond Butter and Fasting Glucose

Completed Phase 2 Results posted Last updated 9 April 2024

What this trial tests

Phase 2 trial testing Almond Butter in Type2 Diabetes in 10 participants. Completed in 1 March 2020.

Timeline

8 March 2019

Primary endpoint
1 March 2020

1 March 2020

Quick facts

Lead sponsor	Penn State University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	10
Start date	8 March 2019
Primary completion	1 March 2020
Estimated completion	1 March 2020
Sites	1 location across United States

Drugs / interventions tested

Almond Butter

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

Penn State University

Who can join

Adults 18 to 75, any sex, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Fasting Glucose Measured Using Continuous Glucose Monitoring Primary · 2 weeks

Fasting glucose measures how much glucose (sugar) is in a blood sample after an overnight fast. In this study, fasting glucose was measured by continuous glucose monitoring (interstitial glucose); fasting window identified through review of glucose monitoring data to be 4am-6am.

Group	Value	95% CI
Almond Butter	148.6	94.9 – 202.3
No-snack Control	142.1	94 – 190.3

Glucose Trends Secondary · 2 weeks

Overnight (12pm-4am) mean blood sugar values measured by continuous glucose monitoring (interstitial glucose)

Group	Value	95% CI
Almond Butter	147.7	92.6 – 202.8
No-snack Control	142.2	91.8 – 191

Inhibitory Control Task (Percent Correct) Secondary · 2 weeks

Go-NoGo task asked participants to press a button when a letter other than X was on screen and not press a button when X was present.

Group	Value	95% CI
Almond Butter	35.34	± 1.51
No Snack Control	35.51	± 1.98

Sponsor's own description

A two-period randomized crossover study will be conducted to determine the effect of almond butter as an evening snack on fasting blood glucose in adults with type 2 diabetes, not taking insulin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other Penn State University trials

Trials by the same sponsor.

NCT07147387 — Lions Hearts: A Community Approach to Multigenerational Cardiovascular Disease Risk · NA · not yet recruiting
NCT07266506 — Development of an Eating Behavior Risk Score · NA · not yet recruiting
NCT07229781 — Mediterranean Diet and Blood Sugar Study · NA · not yet recruiting
NCT07235358 — Cardiometabolic Effects of Pecan Snacking in Prediabetes · NA · not yet recruiting
NCT06823518 — Thrive Initiative Parent-Education Programming Study · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03826472 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Penn State University
Last refreshed: 9 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03826472.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing